New aspects of pain management in acute and chronic inflammatory syndromes
https://doi.org/10.14412/1996-7012-2021-1-73-78
Abstract
Effective pain control is one of the first and most important challenges in medical practice. Non-steroidal anti-inflammatory drugs (NSAIDs) are the cornerstone of treatment for acute and chronic inflammatory pain syndromes. Of particular interest is a group of patients with a low risk of cardiovascular development and a low to moderate risk of gastrointestinal complications, for whom any NSAID may be recommended. Their choice may depend on the duration and severity of the inflammatory process. The most high analgesic potential have non-selective inhibitors of cyclooxygenase – diclofenac and ketoprofen. Modern technologies give great opportunities for modifying the active substance of NSAIDs and improvement of the drug dosage form in order to hasten their effects and enhance analgesic and anti-inflammatory effect of drugs. In the new form of diclofenac (Dialrapid sachet), sodium salt was replaced by potassium salt, which provided a high rate of both absorption of the active substance and action, comparable to that with intramuscular administration of the drug. It also expanded the possibilities of its use for acute pain and relapses of pain relief in exacerbation of chronic inflammatory diseases. The inclusion of lysine salt significantly changed the pharmacodynamics of ketoprofen. Unlike conventional ketoprofen, its lysine salts (Artrozilen and OKИ) are fast-dissolving compounds with neutral pH that do not irritate the mucous membrane of the gastrointestinal tract, which makes them suitable for long-term treatment of chronic inflammatory pain syndromes.
Supporting agencies: This article has been supported by CSC
About the Authors
V. N. Amirdjanova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Vera Nikolaevna Amirdzhanova
34A, Kashirskoe shosse, Moscow 115522
A. Е. Karateev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe shosse, Moscow 115522
References
1. Kukushkin ML. Algorithms for diagnosis and treatment of back pain. Russkii meditsinskii zhurnal. 2014;(11):844-8. (In Russ.).
2. Malanga G, Wolff E. Evidence-informed management of chronic low back pain with nonsteroidal anti-inflammatory drugs, muscle relaxants, and simple analgesics. Spine J. 2008 Jan–Feb;8(1):173–84. doi: 10.1016/j.spinee.2007.10.013.
3. Lee C, Straus WL, Balshaw R, et al. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum. 2004 Oct 15;51(5):746-54. doi: 10.1002/art.20698.
4. Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective nonsteroidal antiinflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008 Apr;12(11):1-278, iii. doi: 10.3310/hta12110.
5. Stam W, Jansen J, Taylor S. Efficacy of etoricoxib, celecoxib, lumiracoxib, nonselective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparison. Open Rheumatol J. 2012;6:6-20. doi: 10.2174/1874312901206010006. Epub 2012 Apr 3.
6. Sieper J, Klopsch T, Richter M, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis. 2008 Mar; 67(3):323–9. Epub 2007 Jul 6.
7. Roelofs PD, Deyo RA, Koes BW, et al. Nonsteroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD000396. doi: 10.1002/14651858.CD000396.pub3.
8. Nasonov EL. Analgesic therapy in rheumatology: a journey between Scylla and Charybdis. Klinicheskaya farmakologiya i terapiya 2003;12(1):64–9. (In Russ.).
9. Karateev AE, Nasonov EL, Ivashkin VT, et al. Rational use of nonsteroidal antiinflammatory drugs. Clinical recommendations. Nauchno-prakticheskaya revmatologiya. 2018;56(Pril 1):1-29. (In Russ.).
10. Chen C, Bujanover S, Kareht S, Rapoport AM. Differential Pharmacokinetics of Diclofenac Potassium for Oral Solution vs Immediate-Release Tablets From a Randomized Trial: Effect of Fed and Fasting Conditions. Headache. 2015 Feb;55(2):265-75. doi: 10.1111/head.12483. Epub 2014 Dec 24.
11. Efficacy of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study with diclofenac potassium tablets and placebo. Poster XII. Congress of International Headache Society (HIS), Kyoto-Japan, October 9-12, 2005.
12. Moran M. Double-blind Comparison of Diclofenac Potassium, Ibuprofen and Placebo in the treatment of ankle sprains. J Int Med Res. Mar-Apr 1991;19(2):121-30. doi: 10.1177/030006059101900205.
13. Verfaillie G, Knape S, Corne L. A case of fatal necrotizing fasciitis after intramuscular administration of diclofenac. Eur J Emerg Med. 2002 Sep;9(3):270–3.
14. Rossi L, Conen D. Intramuscular injections-an outdated form of administration? 6 cases of Staphylococcus aureus sepsis following intramuscular injections. Schweiz Med Wochenschr. 1995 Aug 8;125(31–32):1477–82.
15. Rotman-Pikielny P, Levy Y, Eyal A, Shoenfeld Y. Pyomyositis or «injectiositis»– Staphylococcus aureus multiple abscesses following intramuscular injections. Isr Med Assoc J. 2003 Apr;5(4):295–6.
16. Karateev AE, Pogozheva EYu, Filatova ES, et al. Is there an alternative to intramuscular injections of diclofenac to control severe pain? The results of a randomized controlled partially blind study, the fast and the FORSAGE. Nauchno-prakticheskaya revmatologiya. 2020; 58(4):387-94. (In Russ.)
17. Karateev AE, Pogozheva EYu, Lila AM, et al. Retrospective observational study DRIVE (Effective and Rational Analgesia: the Choice). Russkii meditsinskii zhurnal. 2019; (9):62-6. (In Russ.).
18. Sarzi-Puttini P, Atzeni F, Lanata L, et al. Pain and ketoprofen: what is its role in clinical practice? Reumatismo. Jul-Sep 2010;62(3): 172-88. doi: 10.4081/reumatismo.2010.172.
19. Le Loet X. Safety of ketoprofen in the elderly: a prospective study on 20,000 patients. Scand J Rheumatol Suppl. 1989; 83:21-7. doi: 10.3109/03009748909101474.
20. Chichasova NV, Immametdinova GR, Karateev AE, et al. Efficacy and safety of Ketoprofen (Ketonal) in rheumatoid arthritis (clinical and endoscopic examination). Nauchno-prakticheskaya revmatologiya. 2001;(1):47-52. (In Russ.).
21. Marmo E, Ottavo R, Giordano L, et al. Experimental assessment of some pharmacodynamic features of ketoprofen lysine. Pain relief activity, antipyretic effects, antiinflammatory activity, antiplatelet aggregation activity and interference with the biosynthesis of prostaglandins. Arch Sci Med (Torino). Jul-Sep 1980;137(3):387-404.
22. D’Arienzo M. Pennisi M, Zanolo G, Borsa M. Ketoprofen lysine: ketoprofen serum levels and analgesic activity. Drugs Exp Clin Res. 1984;10:863-6.
23. Kokki H. Ketoprofen pharmacokinetics, efficacy, and tolerability in pediatric patients. Paediatr Drugs. 2010 Oct 1;12(5):313-29. doi: 10.2165/11534910-000000000-00000.
24. Karateev AE, Zhuravleva MV, Alekseev VV, et al. The effectiveness of the combination of various dosage forms of Ketoprofen lysine salt (Arthrosylene®) in patients with severe musculoskeletal pain in real clinical practice. Results of the KULON study (Ketoprofen: Treatment Satisfaction and assessment of Adverse events). Klinicheskaya farmakologiya i terapiya. 2013;(4):23-30. (In Russ.).
25. Amirdzhanova VN. Nonsteroidal antiinflammatory drugs: the difficult choice of pain relief for joint operations. Nauchnoprakticheskaya revmatologiya. 2017;55(5): 555-9. (In Russ.).
26. Cimini A, Brandolini L, Gentile R, et al. Gastroprotective effects of L-lysine salification of ketoprofen in ethanol-injured gastric mucosa. J Cell Physiol. 2015 Apr;230(4): 813-20. doi: 10.1002/jcp.24809.
Review
For citations:
Amirdjanova VN, Karateev AЕ. New aspects of pain management in acute and chronic inflammatory syndromes. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2021;15(1):73-78. (In Russ.) https://doi.org/10.14412/1996-7012-2021-1-73-78
Views:
1029
Email this article 